FDA approves Mirum treatment for cerebrotendinous xanthomatosis

The Food and Drug Administration approved Ctexli for the treatment of cerebrotendinous xanthomatosis in adults. “Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease,” the agency stated. The approval of Ctexli was granted to Mirum Pharmaceuticals (MIRM).